Biogen and Eisai presented three-year real-world data from the LEADER study at the CTAD conference, showing a 76% lower rate of progression to moderate or severe Alzheimer's disease. The analysis of 560 U.S. patients also indicated that 81.1% of participants remained stable or improved after approximately 18 months of treatment with LEQEMBI.
New three-year LEADER real-world data on Leqembi show a 76% lower rate of progression to moderate or severe Alzheimer's disease versus a matched control cohort and 81.1% of patients stable or improved. Supportive real-world evidence strengthens the drug's commercial case for Biogen, though these are retrospective observational results without sales or guidance figures, limiting the price effect.
- ▲ LEADER analysis of 560 US patients: 76% lower progression to moderate/severe AD (HR 0.24) versus ADNI-weighted control
- ▲ 77% of monitored patients became amyloid-negative at a median 18.1 months; no ARIA events during subcutaneous maintenance
- ▼ Data are retrospective, non-randomized and pre-specified comparisons against an external control cohort, not new trial results
- ▼ No revenue, prescription or guidance figures accompany the announcement